Cboe CA - Delayed Quote CAD

Pfizer Inc. (PFE.NE)

12.41

-0.14

(-1.12%)

At close: January 10 at 3:59:29 PM EST

The CEOs Who Are Tearing Up the Policies Trump Hates

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; “EVERYBODY WANTS TO BE MY FRIEND!!!”

The Wall Street Journal yesterday

MCD

DIS

GS
Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data

PREMIUM
MT Newswires yesterday

ARVN

PFE
Court Reopens Challenge to Pfizer Fellowship Program Amid Diversity Debate

U.S. court reopens Pfizer fellowship lawsuit amid growing scrutiny of diversity programs

GuruFocus.com yesterday

PFE
Pfizer must face lawsuit over diversity fellowship program, US court rules

(Reuters) -A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that challenged a Pfizer fellowship program designed to boost the pipeline of Black, Latino and Native American people in leadership positions at the drugmaker. At the urging of the group Do No Harm, a 2-1 panel of the New York-based 2nd U.S. Circuit Court of Appeals revisted a decision it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.

Reuters yesterday

PFE
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial

On Friday, Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival by investigator assessment, showing a clinically meaningful and statistically significant improvement with

Benzinga yesterday

PFE
AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price.  In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episodes of Opening Bid, listen on your favorite podcast platform or watch on our website.

Yahoo Finance Video yesterday

PFE

NVS

NVSEF
Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Zacks yesterday

PFE

NVO
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

NEW YORK, January 10, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a c

Business Wire yesterday

PFE
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

BioPharma Dive yesterday

ABBV

PFE

BIIB
Pfizer Inc. (NYSE:PFE) is largely controlled by institutional shareholders who own 68% of the company

Key Insights Significantly high institutional ownership implies Pfizer's stock price is sensitive to their trading...

Simply Wall St. 2 days ago

PFE
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency.

Investor's Business Daily 2 days ago

AMGN

LLY

PFE
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.

Zacks 3 days ago

PFE
Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus

The first human bird flu death in the US has Moderna's vaccine development in focus for investors this week.

Yahoo Finance 3 days ago

PFE

CVAC

MRNA
Update: GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, US FDA Says

(Updates with GSK's comments in seventh, eighth and ninth paragraphs.) GSK (GSK) and Pfizer's (PF

PREMIUM
MT Newswires 3 days ago

PFE
GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says

GSK (GSK) and Pfizer's (PFE) respiratory syncytial virus vaccines will carry warnings of increased

PREMIUM
MT Newswires 3 days ago

PFE
Walmart CEO Doug McMillon meets with Trump ahead of inauguration

The possibility of tariffs remains a top issue for Walmart as President-elect Donald Trump is set to take office.

Yahoo Finance 3 days ago

PFE

META

WMT
There’s a ‘Shadow’ Over Biotech Stocks. Why It Isn‘t All Bad News.

Pharmaceutical and biotech stocks may find it tough to outperform the market in the months ahead. Nonspecialist investors have shifted their focus to other sectors, such as tech, following the outcome of the election and uncertainty about what it will mean for the industry, they said. “We believe President-elect Trump will be capable of enacting significant change, and the unpredictability is expected to cast a shadow over the space,” analysts led by Trung Huynh said in their 2025 outlook on the sector.

Barrons.com 3 days ago

PFE

MRNA
Prediction: These Could Be the Best-Performing Value Stocks Through 2030

Value stocks have lagged well behind growth stocks in recent years. D.R. Horton (NYSE: DHI) is the largest homebuilder in the U.S. based on volume -- a status it's held since 2002. The company operates in 36 states.

Motley Fool 3 days ago

PFE

MRNA

DHI
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Investor's Business Daily 4 days ago

MRNA

BNTX

NVAX
Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death

The company is one of a few drugmakers currently developing a vaccine for the illness, which is spreading rapidly through North America.

Barrons.com 4 days ago

MRNA

PFE

CVAC

Performance Overview

Return	PFE.NE	S&P 500
YTD	+1.06%	-1.35%
1-Year	-5.06%	+22.51%
3-Year	-47.01%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Pfizer Inc. (PFE.NE)

The CEOs Who Are Tearing Up the Policies Trump Hates

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

Court Reopens Challenge to Pfizer Fellowship Program Amid Diversity Debate

Pfizer must face lawsuit over diversity fellowship program, US court rules

Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

Pfizer Inc. (NYSE:PFE) is largely controlled by institutional shareholders who own 68% of the company

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.

Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note

Moderna stock forfeits gains as first US bird flu death puts vaccine development in focus

Update: GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, US FDA Says

GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says

Walmart CEO Doug McMillon meets with Trump ahead of inauguration

There’s a ‘Shadow’ Over Biotech Stocks. Why It Isn‘t All Bad News.

Prediction: These Could Be the Best-Performing Value Stocks Through 2030

Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike

Moderna Stock Jumps Amid Bird Flu Vaccine Hope After First U.S. Death

Performance Overview